Biologics to Treat Substance Use Disorders

Introduction

Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes

Phil Skolnick

Section 1. Vaccines



Therapeutic Vaccines for Treating Nicotine Addiction.

Matthew W. Kalnik, Ph.D.

Vaccines for Treating Cocaine Use Disorders

Coreen B. Domingo; Daryl Shorter; Thomas R. Kosten

Vaccines for Opioid Addiction



Michael Raleigh and Paul Pentel

Vaccines for Methamphetamine Use Disorder

Thomas R. Kosten and Therese A. Kosten

Vaccine for Cocaine Addiction and HIV infection

Timothy Cardozo, Sergey Shmelkov, Kenneth Ca

rr, John Rotrosen, Pedro Mateu-Gelabert, Samuel R. Friedman

Section 2. Monoclonal antibodies

Monoclonal Antibodies: Introduction

S. Michael Owens

Anti-cocaine monoclonal antibodies

Hanna N. Wetzel, William J. Ball and Andrew B. Norman

Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for use in Treating Methamphetamine Abuse

Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gen-try, and S. Michael Owens

Section 3. Enzymes

Enzyme-based cocaine pharmacotherapies: Current status and projections for the future.

James H. Woods, Chang-Guo Zhan



Viral gene transfer of enzymes

W. Steve Brimijoin Cocaine Hydrolases Designed from Butyrylcholinesterase

Fang Zheng and Chang-Guo Zhan

Section 4. Strategies to optimize the development of biologics to treat addictions

Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders

David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal

and Stephen M. Kaminsky

Nanotechnology based nicotine vaccine

Petr O. Ilyinskii and Lloyd P.M. Johnston

Exploration of DNA nanostructures for rational design of vaccines

Xiaowei Liu, Sidney M. H

echt, Hao Yan, Paul R. Pentel, and Yung Chang

Adjuvants for Substance Abuse Vaccines

Frank M. Orson, Berma M. Kinsey, Muthu Ramakrishnan, Reetakshi Arora, Thomas R. Kosten

Skin Vaccination against Nicotine Addiction

Xinyuan Chen, Ji Wang, Jeffrey H. Wu, and Mei X. Wu

Hapten design for anti-addiction vaccine development

Karen C. Collins, Kim D. Janda

B cell mechanisms underlying vaccine efficacy against drugs of abuse

Marco Pravetoni, Ph.D.

prave001@umn.edu

Section 5. Practical Considerations

Practical considerations for the development of vaccines against drugs of abuse

Oscar B. Torres, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice and



Gary R. Matyas

Ethical Aspects of Biologics to Treat Substance Use Disorders

Ivan D. Montoya

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Enzimologia
• Psicofarmacologia
• Psiquiatria

Biologics;Drug Addiction;Enzymes;Monoclonal Antibodies;Substance Abuse;Vaccines;psychopharmacology;pharmacotherapy